120 related articles for article (PubMed ID: 30274827)
41. Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population.
Matsuo H; Takada T; Ichida K; Nakamura T; Nakayama A; Ikebuchi Y; Ito K; Kusanagi Y; Chiba T; Tadokoro S; Takada Y; Oikawa Y; Inoue H; Suzuki K; Okada R; Nishiyama J; Domoto H; Watanabe S; Fujita M; Morimoto Y; Naito M; Nishio K; Hishida A; Wakai K; Asai Y; Niwa K; Kamakura K; Nonoyama S; Sakurai Y; Hosoya T; Kanai Y; Suzuki H; Hamajima N; Shinomiya N
Sci Transl Med; 2009 Nov; 1(5):5ra11. PubMed ID: 20368174
[TBL] [Abstract][Full Text] [Related]
42. Allergic reaction to allopurinol with cross-reactivity to oxypurinol.
Lockard O; Harmon C; Nolph K; Irvin W
Ann Intern Med; 1976 Sep; 85(3):333-5. PubMed ID: 134655
[TBL] [Abstract][Full Text] [Related]
43. A comprehensive analysis of the association of common variants of ABCG2 with gout.
Yu KH; Chang PY; Chang SC; Wu-Chou YH; Wu LA; Chen DP; Lo FS; Lu JJ
Sci Rep; 2017 Aug; 7(1):9988. PubMed ID: 28855613
[TBL] [Abstract][Full Text] [Related]
44. Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.
Keith MP; Gilliland WR
Clin Pharmacol Ther; 2011 Sep; 90(3):363-4. PubMed ID: 21862966
[TBL] [Abstract][Full Text] [Related]
45. Wastewater-based estimation of the prevalence of gout in Australia.
Ahmed F; Tscharke B; O'Brien J; Thompson J; Samanipour S; Choi P; Li J; Mueller JF; Thomas K
Sci Total Environ; 2020 May; 715():136925. PubMed ID: 32007890
[TBL] [Abstract][Full Text] [Related]
46. An allopurinol adherence tool using plasma oxypurinol concentrations.
Smith-Diaz N; Stocker SL; Stamp LK; Dalbeth N; Phipps-Green AJ; Merriman TR; Wright DFB
Br J Clin Pharmacol; 2023 Jul; 89(7):1956-1964. PubMed ID: 36036094
[TBL] [Abstract][Full Text] [Related]
47. Polymorphisms of ABCG2 and its impact on clinical relevance.
Zhang W; Sun S; Zhang W; Shi Z
Biochem Biophys Res Commun; 2018 Sep; 503(2):408-413. PubMed ID: 29964015
[TBL] [Abstract][Full Text] [Related]
48. An audit of a therapeutic drug monitoring service for allopurinol therapy.
Kannangara DR; Ramasamy SN; Ray JE; Jones G; Graham GG; Williams KM; Day RO
Ther Drug Monit; 2013 Dec; 35(6):863-6. PubMed ID: 24263644
[TBL] [Abstract][Full Text] [Related]
49. Population-specific association between ABCG2 variants and tophaceous disease in people with gout.
He W; Phipps-Green A; Stamp LK; Merriman TR; Dalbeth N
Arthritis Res Ther; 2017 Mar; 19(1):43. PubMed ID: 28270222
[TBL] [Abstract][Full Text] [Related]
50. Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia.
Stamp LK; Turner R; Khalilova IS; Zhang M; Drake J; Forbes LV; Kettle AJ
Rheumatology (Oxford); 2014 Nov; 53(11):1958-65. PubMed ID: 24899662
[TBL] [Abstract][Full Text] [Related]
51. Mechanism of inhibition of xanthine oxidoreductase by allopurinol: crystal structure of reduced bovine milk xanthine oxidoreductase bound with oxipurinol.
Okamoto K; Eger BT; Nishino T; Pai EF; Nishino T
Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):888-93. PubMed ID: 18600558
[TBL] [Abstract][Full Text] [Related]
52. ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approaches.
Cleophas MC; Joosten LA; Stamp LK; Dalbeth N; Woodward OM; Merriman TR
Pharmgenomics Pers Med; 2017; 10():129-142. PubMed ID: 28461764
[TBL] [Abstract][Full Text] [Related]
53. Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2, HLA-B and Allopurinol, and MTHFR, folic acid and methotrexate.
van der Pol KH; Nijenhuis M; Soree B; de Boer-Veger NJ; Buunk AM; Guchelaar HJ; Risselada A; van Schaik RHN; Swen JJ; Touw D; van der Weide J; van Westrhenen R; Deneer VHM; Houwink EJF; Rongen GA
Eur J Hum Genet; 2024 Feb; 32(2):155-162. PubMed ID: 36056234
[TBL] [Abstract][Full Text] [Related]
54. ABCG2 dysfunction increases the risk of renal overload hyperuricemia.
Matsuo H; Takada T; Nakayama A; Shimizu T; Sakiyama M; Shimizu S; Chiba T; Nakashima H; Nakamura T; Takada Y; Sakurai Y; Hosoya T; Shinomiya N; Ichida K
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):266-74. PubMed ID: 24940678
[TBL] [Abstract][Full Text] [Related]
55. Multiple common and rare variants of
Higashino T; Takada T; Nakaoka H; Toyoda Y; Stiburkova B; Miyata H; Ikebuchi Y; Nakashima H; Shimizu S; Kawaguchi M; Sakiyama M; Nakayama A; Akashi A; Tanahashi Y; Kawamura Y; Nakamura T; Wakai K; Okada R; Yamamoto K; Hosomichi K; Hosoya T; Ichida K; Ooyama H; Suzuki H; Inoue I; Merriman TR; Shinomiya N; Matsuo H
RMD Open; 2017; 3(2):e000464. PubMed ID: 29225919
[TBL] [Abstract][Full Text] [Related]
56. Effects of allopurinol and of oxypurinol on turkey liver xanthine dehydrogenase.
Fhaoláin IN; Coughlan MP
FEBS Lett; 1978 Jun; 90(2):305-8. PubMed ID: 668894
[No Abstract] [Full Text] [Related]
57. The C421A (Q141K) polymorphism enhances the 3'-untranslated region (3'-UTR)-dependent regulation of ATP-binding cassette transporter ABCG2.
Ripperger A; Benndorf RA
Biochem Pharmacol; 2016 Mar; 104():139-47. PubMed ID: 26903388
[TBL] [Abstract][Full Text] [Related]
58. Difference of the plasma concentration and urinary excretion of allopurinol, oxypurinol, and purine bases between dietary intake and fasting.
Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Yamakita J; Higashino K
Int J Clin Pharmacol Ther; 1996 Apr; 34(4):157-62. PubMed ID: 8861734
[TBL] [Abstract][Full Text] [Related]
59. Additive composite ABCG2, SLC2A9 and SLC22A12 scores of high-risk alleles with alcohol use modulate gout risk.
Tu HP; Chung CM; Min-Shan Ko A; Lee SS; Lai HM; Lee CH; Huang CM; Liu CS; Ko YC
J Hum Genet; 2016 Sep; 61(9):803-10. PubMed ID: 27225847
[TBL] [Abstract][Full Text] [Related]
60. Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone.
Iwanaga T; Kobayashi D; Hirayama M; Maeda T; Tamai I
Drug Metab Dispos; 2005 Dec; 33(12):1791-5. PubMed ID: 16135657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
